Dutch Delegation Promises ‘Seamless’ Transition To EMA’s New Home
Dutch officials took part in the December meeting of the EMA management board and presented details of their plans for the agency’s relocation to Amsterdam. The board also adopted the 2018 work program and budget, which allow for a 6.8% rise in fee-related revenue next year, and said phase 2 of the Brexit business continuity plan would begin in January.
You may also be interested in...
The Italian government has asked the Court of Justice of the EU to annul the decision to site the European Medicines Agency in Amsterdam and wants to move the agency instead to Milan. But the Dutch government insists that the selection process was “fair” and that the need for temporary premises had been made clear all along.
Sponsors of centrally authorized medicines in the EU are being urged to respond to a survey by the European Medicines Agency aimed at gauging industry's preparedness for Brexit. Companies have until Feb. 9 to complete survey, which the EMA says is critical to help with resource planning and ensuring a smooth transition.
The EMA is planning another survey to see how many of its staff are likely to follow it to Amsterdam, while the agency’s executive director says having to move into temporary premises while a permanent home is constructed is inconvenient but should allow core regulatory activities to be pursued.